AstraZeneca-Hutchmed Lung Cancer Combination Improves Progression-Free Survival in Late-Stage Trial
01 Event
AstraZeneca and China’s Hutchmed said on September 1, 2026 that a late-stage clinical trial of Tagrisso combined with Orpathys significantly improved progression-free survival in a specific group of patients with advanced non-small cell lung cancer.
The study involved patients with EGFR-mutated advanced non-small cell lung cancer whose tumors showed moderate to high levels of the MET protein marker. The patients had not previously received treatment for their advanced disease.
The companies said the combination performed better than Tagrisso alone as a first-line treatment. They also reported encouraging results for overall survival, a key secondary endpoint. Reuters’ report did not provide the detailed numerical trial results, so this article should not invent effect sizes, response rates or survival durations that were not disclosed in the reporting.
02 What Changed?
Tagrisso is already one of AstraZeneca’s best-selling cancer drugs. The new study tests whether adding Orpathys earlier in treatment can improve outcomes for a defined subgroup of patients whose tumors carry both the EGFR mutation and elevated MET expression.
The shift is important because combination therapy can address more than one biological pathway at the same time. In this trial, the companies are testing whether targeting EGFR with Tagrisso and MET with Orpathys can slow disease progression more effectively than Tagrisso alone in patients selected by tumor characteristics.
Principal investigator Yi-Long Wu said the observed clinical benefit could reshape the primary treatment strategy for this distinct patient population. That statement reflects the investigator’s interpretation of the study results; it is not the same as a regulatory approval or a universal treatment recommendation.
03 Why It Matters
Progression-free survival measures how long patients live without their disease worsening. It is commonly used in cancer trials because a therapy can show that it delays progression even before enough time has passed to establish a final overall-survival result.
Overall survival measures how long patients live regardless of whether their disease progresses. Reuters reported that the combination showed encouraging benefits on that secondary endpoint, but the wording matters: “encouraging” is not the same as a final statistically confirmed survival advantage unless the companies release data showing that threshold was met.
The study is also an example of increasingly targeted cancer treatment. The trial did not enroll every patient with lung cancer. It focused on advanced non-small cell lung cancer with an EGFR mutation and moderate-to-high MET protein levels. That narrower population is essential to understanding what the result does and does not mean.
It would therefore be inaccurate to describe the study as showing that the combination works for all lung-cancer patients or that it represents a cure. The evidence reported so far supports a benefit in a defined biomarker-selected group.
04 What It Means for You
For patients, the immediate practical effect may be limited until detailed study results are presented, regulators review the evidence and treatment guidelines determine how the combination should be used. A positive late-stage trial is an important step, but it does not by itself replace individualized medical decision-making.
People diagnosed with advanced lung cancer are typically assessed using tumor characteristics because treatment options can depend on specific mutations and biomarkers. The relevance of this study comes from that precision: the trial identified patients by EGFR mutation and MET expression rather than treating all non-small cell lung cancers as biologically identical.
For investors and the pharmaceutical industry, the result matters because oncology makes up nearly half of AstraZeneca’s sales. Tagrisso is one of its most important products, while Orpathys is being developed with Hutchmed as AstraZeneca pursues a target of $80 billion in annual sales by 2030.
For related Earnyx science coverage, see Moderna’s cancer-vaccine news and what it actually showed and research using engineered probiotic bacteria in pancreatic-cancer studies. Both stories underline the same editorial rule: promising research must be reported at the stage the evidence actually supports.
05 Numbers + Context
Reuters did not provide patient counts, hazard ratios, median progression-free-survival times or detailed safety results in its September 1 report. Those omissions are important. Without the full dataset, readers should not try to calculate the magnitude of benefit from the headline alone.
The confirmed trial structure is that Tagrisso plus Orpathys was compared with Tagrisso alone as first-line treatment in previously untreated patients with EGFR-mutated advanced non-small cell lung cancer and moderate-to-high MET expression.
The primary reported result was a significant improvement in progression-free survival. The companies also described overall-survival findings as encouraging. Detailed data will be necessary to understand how large the benefit is, how side effects compare between the two treatment approaches and whether the benefit is consistent across subgroups.
On the business side, AstraZeneca has said it is aiming for $80 billion in annual sales by 2030. Cancer therapies currently account for nearly half of its sales, so expanding the use of established oncology drugs and developing effective combinations is commercially significant as well as medically important.
06 Earnyx Takeaway
This is a meaningful late-stage trial result, but the correct headline is narrower than “new lung cancer breakthrough.” The companies say the combination delayed disease progression more effectively than Tagrisso alone in a specific biomarker-defined patient population.
The next questions are the size of that benefit, the full safety profile, the maturity of overall-survival data and how regulators and clinicians interpret the results. Until those details are available, the evidence supports cautious optimism rather than broad claims.
The most useful takeaway for readers is to pay attention to who was actually studied. Modern cancer research increasingly depends on mutations and protein markers that identify patients more likely to benefit from a particular treatment strategy. This trial is another example of that precision approach.
Source: Reuters, September 1, 2026.